Regencell Bioscience [RGC] vs Elanco Animal Health [ELAN] Detailed Stock Comparison
Regencell Bioscience
NASDAQ
Loading...
Elanco Animal Health
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Regencell Bioscience wins in 4 metrics, Elanco Animal Health wins in 10 metrics, with 0 ties. Elanco Animal Health appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Regencell Bioscience | Elanco Animal Health | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1,779.13 | 22.28 | Regencell Bioscience |
| Price-to-Book Ratio | 1,121.43 | 1.44 | Elanco Animal Health |
| Debt-to-Equity Ratio | 0.00 | 62.13 | Regencell Bioscience |
| PEG Ratio | N/A | -0.19 | N/A |
| EV/EBITDA | -1,913.48 | 15.93 | Regencell Bioscience |
| Profit Margin (TTM) | 0.00% | 9.68% | Elanco Animal Health |
| Operating Margin (TTM) | 0.00% | 6.85% | Elanco Animal Health |
| EBITDA Margin (TTM) | N/A | 6.85% | N/A |
| Return on Equity | -47.77% | 6.83% | Elanco Animal Health |
| Return on Assets (TTM) | -30.65% | 0.98% | Elanco Animal Health |
| Free Cash Flow (TTM) | $-4.01M | $380.00M | Elanco Animal Health |
| 1-Year Return | 14,581.82% | 39.63% | Regencell Bioscience |
| Price-to-Sales Ratio (TTM) | N/A | 2.17 | N/A |
| Enterprise Value | $7.64B | $13.41B | Elanco Animal Health |
| EV/Revenue Ratio | N/A | 2.99 | N/A |
| Gross Profit Margin (TTM) | N/A | 57.45% | N/A |
| Revenue per Share (TTM) | $0 | $9 | Elanco Animal Health |
| Earnings per Share (Diluted) | $-0.01 | $0.88 | Elanco Animal Health |
| Beta (Stock Volatility) | 2.15 | 1.62 | Elanco Animal Health |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Regencell Bioscience vs Elanco Animal Health Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 2.02% | 6.67% | 25.68% | 55.89% | 2,504.84% | 12,323.08% |
| Elanco Animal Health | -1.59% | 8.19% | 14.68% | 39.06% | 90.06% | 69.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Regencell Bioscience | 14,581.82% | 1,845.78% | 5,667.86% | 5,667.86% | 5,667.86% | 5,667.86% |
| Elanco Animal Health | 39.63% | 66.69% | -38.16% | -39.97% | -39.97% | -39.97% |
News Based Sentiment: Regencell Bioscience vs Elanco Animal Health
Regencell Bioscience
News based Sentiment: POSITIVE
The month of October 2025 showed positive movement in investor sentiment with a decrease in short interest and a higher-than-average news sentiment score. However, the lack of insider and institutional activity tempers the overall outlook, suggesting a need for continued monitoring.
Elanco Animal Health
News based Sentiment: POSITIVE
Elanco experienced a strong month with a new 52-week high, positive earnings results, and upgrades from multiple analysts. The company is also investing in key areas like automation and high-performance computing, signaling a commitment to future growth. While institutional activity is mixed, the overall narrative is positive.
Performance & Financial Health Analysis: Regencell Bioscience vs Elanco Animal Health
| Metric | RGC | ELAN |
|---|---|---|
| Market Information | ||
| Market Cap | $7.64B | $9.74B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 183,082 | 5,423,590 |
| 90 Day Avg. Volume | 247,494 | 8,718,383 |
| Last Close | $16.15 | $20.47 |
| 52 Week Range | $0.09 - $83.60 | $8.02 - $20.92 |
| % from 52W High | -80.68% | -2.15% |
| All-Time High | $950.00 (May 30, 2025) | $37.61 (Sep 24, 2018) |
| % from All-Time High | -98.30% | -45.57% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.05% |
| Quarterly Earnings Growth | N/A | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.10% |
| Operating Margin (TTM) | 0.00% | 0.07% |
| Return on Equity (TTM) | -0.48% | 0.07% |
| Debt to Equity (MRQ) | 0.00 | 62.13 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.01 | $13.64 |
| Cash per Share (MRQ) | N/A | $1.09 |
| Operating Cash Flow (TTM) | $-3,881,392 | $572.00M |
| Levered Free Cash Flow (TTM) | $-4,301,837 | $1.21B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Regencell Bioscience vs Elanco Animal Health
| Metric | RGC | ELAN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1,779.13 | 22.28 |
| Forward P/E | N/A | 20.86 |
| PEG Ratio | N/A | -0.19 |
| Price to Sales (TTM) | N/A | 2.17 |
| Price to Book (MRQ) | 1,121.43 | 1.44 |
| Market Capitalization | ||
| Market Capitalization | $7.64B | $9.74B |
| Enterprise Value | $7.64B | $13.41B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 2.99 |
| Enterprise to EBITDA | -1,913.48 | 15.93 |
| Risk & Other Metrics | ||
| Beta | 2.15 | 1.62 |
| Book Value per Share (MRQ) | $0.01 | $13.64 |
Financial Statements Comparison: Regencell Bioscience vs Elanco Animal Health
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RGC | ELAN |
|---|---|---|
| Revenue/Sales | N/A | $1.24B |
| Cost of Goods Sold | N/A | $528.00M |
| Gross Profit | N/A | $713.00M |
| Research & Development | N/A | $92.00M |
| Operating Income (EBIT) | N/A | $85.00M |
| EBITDA | N/A | $243.00M |
| Pre-Tax Income | N/A | $25.00M |
| Income Tax | N/A | $14.00M |
| Net Income (Profit) | N/A | $11.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RGC | ELAN |
|---|---|---|
| Cash & Equivalents | $2.96M | $539.00M |
| Total Current Assets | $8.11M | $3.61B |
| Total Current Liabilities | $193,578 | $1.39B |
| Long-Term Debt | $25,934 | $4.15B |
| Total Shareholders Equity | $8.22M | $6.78B |
| Retained Earnings | $-21.62M | $-1.87B |
| Property, Plant & Equipment | $84,780 | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RGC | ELAN |
|---|---|---|
| Operating Cash Flow | N/A | $185.00M |
| Capital Expenditures | N/A | $-57.00M |
| Free Cash Flow | N/A | $180.00M |
| Debt Repayment | N/A | $-446.00M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RGC | ELAN |
|---|---|---|
| Shares Short | 1.68M | 27.38M |
| Short Ratio | 6.07 | 2.68 |
| Short % of Float | 0.02% | 0.08% |
| Average Daily Volume (10 Day) | 183,082 | 5,423,590 |
| Average Daily Volume (90 Day) | 247,494 | 8,718,383 |
| Shares Outstanding | 494.49M | 494.45M |
| Float Shares | 18.43M | 492.94M |
| % Held by Insiders | 0.96% | 0.01% |
| % Held by Institutions | 0.00% | 1.10% |
Dividend Analysis & Yield Comparison: Regencell Bioscience vs Elanco Animal Health
| Metric | RGC | ELAN |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |